ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Balancing Microthrombosis and Inflammation via Injectable Protein Hydrogel for Inflammatory Bowel Disease.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 72 citations in OpenAlex.
- Design, Properties and Applications of Multiple Dynamic Hydrogels.Materials (Basel, Switzerland) · 2026Review
- Clinical combination therapy for IBD and promising co-delivery strategies.Inflammopharmacology · 2026Review
- Glycosaminoglycans in tissue regeneration: Insights into glycobiology and their biomedical application.Bioactive materials · 2026Review
- Hydrogel-enabled drug delivery for ulcerative colitis.Inflammopharmacology · 2026Review
- Synthetic mucus biomaterials enable localized therapeutic antibody delivery in inflammatory bowel disease.APL bioengineering · 2026Article
- Manganese oxide nanozyme-loaded CO-releasing halloysite nanotubes for remodeling colonic immune, microbiota, and intestinal barrier homeostasis with concurrent pain relief in ulcerative colitis.Bioactive materials · 2026Article
- Natural Polymer-Based Hydrogels for Localized Therapy in Inflammatory Bowel Disease: From Smart Materials to Clinical Translation.Journal of inflammation research · 2026Review
- Virus-derived serpin reduces immuno-coagulopathic damage in murine colitis by targeting the urokinase-type plasminogen activator receptor (uPAR) and complement.Scientific reports · 2025Article
- A Charge-Adhesive Targeted DNA Gel Bandage for the Precision Treatment of Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Sonodynamic and Bioorthogonal Sonocatalytic Thrombotic Therapy Based on AIE Cationic Tetranuclear Ir(III) Complex Nanoplatform Guided by NIR-Chemiluminescence Imaging.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Review
- Advancements in the Field of Protein-Based Hydrogels: Main Types, Characteristics, and Their Applications.Gels (Basel, Switzerland) · 2025Review
- Inflammation Targeting-Triggered Healing Hydrogel for In Situ Reconstruction of Colonic Mucosa.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Layer by layer self-assembled hyaluronic acid nanoarmor for the treatment of ulcerative colitis.Journal of nanobiotechnology · 2024Article
- Natural medicines-derived carbon dots as novel oral antioxidant administration strategy for ulcerative colitis therapy.Journal of nanobiotechnology · 2024Article
- Artificial mucus layer formed in response to ROS for the oral treatment of inflammatory bowel disease.Science advances · 2024Article
- Synergistic Drug-Loaded Shear-Thinning Star Polymer Hydrogel Facilitates Gastrointestinal Lesion Resection and Promotes Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Gas-propelled nanomotors alleviate colitis through the regulation of intestinal immunoenvironment-hematopexis-microbiota circuits.Acta pharmaceutica Sinica. B · 2024Article
- HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
Abstract
Emerging evidence indicates that a vicious cycle between inflammation and microthrombosis catalyzes the pathogenesis of inflammatory bowel disease (IBD). Over-stimulated inflammation triggers a coagulation cascade and leads to microthrombosis, which further complicates the injury through tissue hypoxia and ischemia. Herein, an injectable protein hydrogel with anti-thrombosis and anti-inflammation competency is developed to impede this cycle, cross-linked by silver ion mediated metal-ligand coordination and electronic interaction with sulfhydryl functionalized bovine serum albumin and heparin, respectively. The ex vivo experiments show that the hydrogel, HEP-Ag-BSA, exhibits excellent self-healing ability, injectability, biocompatibility, and sustained drug release. HEP-Ag-BSA also demonstrates anti-coagulation and anti-inflammation abilities via coagulation analysis and lipopolysaccharide stimulation assay. The in vivo imaging confirms the longer retention time of HEP-Ag-BSA at inflammatory sites than in normal mucosa owing to electrostatic interactions. The in vivo study applying a mouse model with colitis also reveals that HEP-Ag-BSA can robustly inhibit inflammatory microthrombosis with reduced bleeding risk. This versatile protein hydrogel platform can definitively hinder the "inflammation and microthrombosis" cycle, providing a novel integrated approach against IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.